Advertisement
UK markets close in 2 hours 51 minutes

  • FTSE 100

    8,099.64
    +59.26 (+0.74%)
     

  • FTSE 250

    19,741.61
    +22.24 (+0.11%)
     

  • AIM

    755.81
    +1.12 (+0.15%)
     

  • GBP/EUR

    1.1667
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2478
    +0.0016 (+0.13%)
     

  • Bitcoin GBP

    51,194.75
    -2,210.37 (-4.14%)
     

  • CMC Crypto 200

    1,362.29
    -20.28 (-1.47%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    83.23
    +0.42 (+0.51%)
     

  • GOLD FUTURES

    2,338.50
    +0.10 (+0.00%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,997.78
    -90.92 (-0.50%)
     

  • CAC 40

    8,029.84
    -62.02 (-0.77%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

Amgen ends collaboration with AstraZeneca on inflammation drug

Reuters - UK Focus

May 22 (Reuters) - Amgen Inc (Xetra: 867900 - news) said it will terminate a collaboration with AstraZeneca Plc (NYSE: AZN - news) to develop an inflammation drug after it observed suicidal thoughts in subjects of a trial.

AstraZeneca could decide on the development and marketing of the drug for all territories, except for Japan and certain Asian territories, where Kyowa Hakko Kirin has the rights to it, Amgen (Hanover: AMG.HA - news) said.

Amgen said such safety concerns would likely result in a restrictive label, potentially limiting the number of patients using the drug. (Reporting by Amrutha Penumudi in Bengaluru; Editing by Don Sebastian)